Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843).
Literal federal measure citations: S. 43, H.R. 6485, S. 1302, H.R. 1843
2025 · 4th Quarter (Oct 1 - Dec 31)
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
Filed by COVINGTON & BURLING LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $170,000.00
- Expenses
- Not reported
- Registrant
- COVINGTON & BURLING LLP
- Filing UUID
- d83eebed-d045-4b79-8892-df9881b8b259
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.
Literal federal measure citations: S. 355, H.R. 2821, S. 1414, S. 43, H.R. 6485, S. 1302, H.R. 1843, S. 1071, H.R. 3838
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.